Nimotuzumab is an anti group of anti-epidermal growth factor receptor the EGF protein receptor, such as colorectal, brain, pancrea cervical and breast cancer. In order to obtain a of the above-mentioned cancers, nimotuzumab and gamma-emitter 177 Lu. This report discuss vivo tests, which included cytotoxicity, clearance, imaging and biodistribution tests. The cytotoxicity test of (lung carcinoma) was found unradiolabeled nimotuzumab. The on normal rats showed that the residue the urine. The biodistribution and image tests showed that 177 Lu-DOTA-nimotuzumab there organs, such as the kidney, liver and bone post injection of 177 Lu-DOTA nearly the same as or slightly lower compared to other radiolabeled monoclonal antibodies, precautions still ha tested on cancer patients.